Key weight loss results at 48 weeks by group: Response rates at 48 weeks (12 mg dose): 100% achieved greater than or equal to 5% weight loss 93% achieved greater than or equal to 10% weight loss 83% achieved greater than or equal to 15% weight loss The cardiometabolic improvements were also significant, with reductions in blood pressure, triglycerides, LDL cholesterol, HbA1c, fasting glucose, and fasting insulin across all dose groups
Vitamin B12 $25 | 15 min
While some peptides like Semaglutide have received FDA approval for specific conditions (such as type 2 diabetes and weight loss), many peptides are prescribed "off-label." This means they are used for purposes beyond their initial FDA-approved use
Pharmacological agents currently in clinical trials for disorders in neurogastroenterology
N.GruhlkeM
Unlike prior studies of AMD development that were limited to patients with diabetes, the authors wrote in their paper, their findings suggest that GLP-1 drugs "may be associated with reduced risk even in individuals with obesity but not diabetes, potentially supporting a protective benefit independent of glycemic control and mitigating diabetes as a confounding factor.